An interventional study of blood sampling in Septic Shock, sponsored by Central Hospital, Nancy, France. Status unknown. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-02-25.
Sponsored by Central Hospital, Nancy, France · Not applicable, Interventional, and Diagnostic
Sepsis induces hemostatic disorders due to the exessive or inappropriate activation of inflammation, which could lead either to hypercoagulability or hypocoagulability. It is currently not possible to determine the hemostatic status of a given patient. This instability of hemostatic system is not revealed by classical tests. Thus, a better characterization of hemostatic status could certainly improve patient care. This study aims at characterizing disorders of coagulation and fibrinolysis using "global" tests such as thrombin generation test or coagulolytic test. Furthermore, the association with biological markers of interest (such as microparticles, neutrophil elastase or histones) will be evaluated.
862 studies on the registry are indexed under Shock, Septic; 207 are open to participants now.
This study's planned enrollment of 50 is below the median of 80 across 530 interventional studies indexed under Shock, Septic.
Browse Shock, Septic studies →Central Hospital, Nancy, France is the lead sponsor of 778 studies on the registry; 183 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Eligibility criteria for patients with septic schock
Inclusion Criteria:
Exclusion Criteria:
Eligibility criteria from subject without septic shock Subject blood samples without septic shock are collected from a historical healthy volunteers cohort.
Biological: blood sampling
Biological: blood sampling
additional blood sampling (volume: 18 mL)
Changes in endogenous thrombin potential as assessed by thrombin generation test
thrombin generation will be measured using CAT method (fluorescence) in plasma from patients within 48 hours. Endogenous thrombin potential is defined as the area under the thrombin generation curve and will be compared with values obtained in healthy subjects
Time frame: 48 hours
Changes in Thrombin peak as assessed by thrombin generation test
thrombin generation will be measured using CAT method (fluorescence) in plasma from patients within 48 hours. Thrombin peak is defined as the highest thrombin concentration derived from the thrombin generation curve and will be compared with values obtained in healthy subjects.
Time frame: 48 hours
Changes in clot lysis time as assessed by clot lysis assay
Clot lysis assay will, be performed in plasma from patients and will be compared with those obtained in healthy subjects.
Time frame: 48 hours
Correlation of neutrophil elastase with changes in endogenous thrombin potential
Neutrophil elastase will be measured in plasma from patients.
Time frame: 48 hours
Correlation of cell-derived microparticles with changes in endogenous thrombin potential
microparticles derived from leukocytes, erythrocytes, platelets and endothelial cells will be measured in plasma from patients by flow cytometry.
Time frame: 48 hours
Correlation of circulating histones with changes in endogenous thrombin potential
Circulating histones will be measured in plasma from patients
Time frame: 48 hours
No study locations are listed for this record.
This study is status unknown, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Central Hospital, Nancy, France